Found vs Kin Meds
Found and Kin Meds both sell semaglutide, tirzepatide and orforglipron; this is how their prices, coverage and records differ.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
If you are choosing between Found and Kin Meds, price alone will not settle it. Both prescribe semaglutide, tirzepatide and orforglipron, so moving from one to the other would not change your drug. Found leads our six-part score, 8.6 to 6.5. One of the two has an FDA warning letter on record, covered below.
Found vs Kin Meds price
Found and Kin Meds start at the same figure, $149 a month, so the entry price does not separate them. Look at what each price covers and at the per-drug prices below.
Drug by drug: Semaglutide is cheaper at Kin Meds ($149 a month vs $169 a month); tirzepatide is cheaper at Kin Meds ($149 a month vs $169 a month); orforglipron costs the same at both, $149 a month.
Medications and formats
Both sell semaglutide, tirzepatide and orforglipron.
On format, Found prices compounded injections, an oral option and brand-name pens, while Kin Meds prices compounded injections and brand-name pens.
Where each one treats patients
Found lists 50 states, and Kin Meds does not publish where it ships.
Pricing
Found
$169/mo cash-pay on the 12-month prepaid plan, with medication, membership and coaching included; $99/mo with insurance on the same 12-month prepaid plan. Month-to-month: $199/mo with insurance, $289/mo cash. A '$100 off today' promo was running at checkout.
Same Compounded GLP-1 Plan price as semaglutide, with no per-drug price published; the drug and price are set after intake. Cash: $169/mo prepaid for 12 months or $289/mo month to month. Insurance: $99/mo prepaid.
Starting cash price of about $149/mo, listed on Found's Foundayo comparison table. Newly added to Found's menu.
Homepage carousel 'Wegovy® from $650/mo+'; but /medication/foundayo table lists 'Wegovy® Pen ... Starting cash price ~$199/mo' — internally inconsistent on their own site.
Homepage carousel 'Zepbound® from $650/mo+'; /medication/foundayo table shows Zepbound ~$299/mo starting cash price.
Brand-name Ozempic at $1,100/mo, as advertised on the homepage.
Homepage carousel 'Mounjaro® ~$1100/mo' — unchanged. Non-GLP-1 generics plan from $49/mo; microdosing program price not published.
Kin Meds
$53 off first order, applied automatically at checkout per kinmeds.com/glp1-discount ('Save $53 on first order -Discount applied at checkout')
$53 off first order, auto-applied; discount page quotes starting dose 'as low as $49/week' first month
Kin Meds advertises "Starting at $149/mo" for Wegovy injection, Wegovy pill, Zepbound KwikPen, Zepbound vial and Foundayo alike. The price carries a footnote marker, but the footnote itself is missing from the site, so its conditions are unstated. Compounded semaglutide is $199 and tirzepatide $249.
Entry pricing — likely insured/savings-card tier; cash-pay LillyDirect vials run $299-$449/mo
Matches the LillyDirect $149/mo starter cash price for Foundayo
What each price covers
Found's price also covers the clinician visit, the medication itself and coaching, which Kin Meds does not claim.
Found is silent on shipping and lab work.
Kin Meds does not say what its price includes.
That matters most for the drug: unless Kin Meds confirms otherwise, budget for medication on top of its listed price.
Found
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
Not stated
Lab work
Not stated
Coaching
In the price
Kin Meds
Inclusions not disclosed.
Where each one scores higher
Overall, Found scores 8.6 and Kin Meds 6.5 out of 10.
Found is stronger on value (7.8 vs 5.0), trust & safety (8.5 vs 3.5), accessibility (10.0 vs 5.0) and support (7.0 vs 5.0).
Effectiveness and user experience are within half a point.
Found
8.6/10
Kin Meds
6.5/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
FDA warning letters
The FDA sent Kin Meds a warning letter dated February 20, 2026 (letter 721450), and it is still open.
Found has no FDA warning letter on record with us.
Features & Coverage
| Feature | Found | Kin Meds |
|---|---|---|
| Starting Price | $149/mo | $149/mo |
| Features | 3 features | ✓8 features |
| States Available | 50 | Not disclosed |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warning Letters | ✓None | 1 letter |
About Found
Found is a personalized weight care platform. It runs on a self-pay membership, and medication costs sit on top of that.
Read our full Found review →About Kin Meds
Kin Meds starts compounded semaglutide at $199/mo and compounded tirzepatide at $249/mo, and carries brand-name FDA-approved options including Wegovy injection and pill, Zepbound and Foundayo from $149/mo. It is LegitScript-verified. Beyond weight loss the account also covers Sermorelin, NAD+, glutathione, TRT, hair, skin and sexual health, so members can run several protocols in one place.
Read our full Kin Meds review →Pros & Cons
Found
What we like
- Tirzepatide costs $169 a month, 32% below the $250 median for compounded tirzepatide across the sellers we compare
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes the medication, clinician visits and coaching
- Serves all 50 states
- We found no FDA warning letters issued to Found
Watch-outs
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- Its orforglipron, semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Kin Meds
What we like
- Semaglutide costs $149 a month, 85% below the $990 median for brand-name semaglutide across the sellers we compare
- Orforglipron costs $149 a month, close to the $149 median for brand-name orforglipron across the sellers we compare
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
Watch-outs
- Confirm it serves your state before you start the intake
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- The FDA has issued Kin Meds a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
Found wins this one, 8.6 to 6.5, above all for tirzepatide at $169/month, 37% below the typical price. Kin Meds fits better if oral orforglipron alongside the injectables is your priority.
Choose Found if…
You want tirzepatide at $169/month, 37% below the typical price and an opening price near $149 a month.
Choose Kin Meds if…
You want oral orforglipron alongside the injectables and an opening price near $149 a month.
Ready to start? GLP-1 providers we have vetted
Telehealth providers, vetted by us, prescribing GLP-1 online.
Vetted by our editors · no insurance required
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Willow
Seeing what it charges before you answer any medical questions
From $299/mo
Get started →Sesame Care
Oral orforglipron alongside the injectables
From $59/mo
Get started →Collective
Flat any-dose pricing, if you can absorb a $199 annual membership on top
From $59/mo
Get started →Found vs Kin Meds: FAQ
Close alternatives to Found and Kin Meds
- Found vs Sesame Care
- Found vs ShedRx
- Found vs PreventiveMD
- Kin Meds vs PreventiveMD
- Kin Meds vs Sesame Care
- Kin Meds vs ShedRx
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.